Coloplast A/S provides financial guidance for the fiscal year 2023. Organic revenue growth is expected at 7-8% in constant exchange rates. Reported growth in DKK is expected at 11-12% and includes contribution from the Atos Medical acquisition of around 3%-points (4 months impact) and around 1%-point positive impact from currencies.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
827.4 DKK | -1.78% | -5.11% | +7.69% |
15/05 | COLOPLAST : Multiple silver linings in spite of a soft Q2 24 | |
07/05 | European shares hit one-month high as earnings take centre stage | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.69% | 27.61B | |
-36.27% | 2.88B | |
-21.21% | 2.37B | |
+5.74% | 2.21B | |
-11.31% | 1.87B | |
+21.11% | 1.86B | |
+23.95% | 1.31B | |
-14.16% | 1.23B | |
-6.45% | 1.22B | |
+21.08% | 1.22B |
- Stock Market
- Equities
- COLO B Stock
- News Coloplast A/S
- Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023